Start the conversation
It's not often that you get a chance to get in on the "ground floor" of an entire new business.
But that's just what you have here.
In the past, you've heard me say that we are living in the "Golden Age of Materials Science." You see, without Miracle Materials – and the science that backs them – we simply wouldn't have some of the unique high-tech products we take for granted: smartphones, electric cars, and new drug therapies just to name a few.
Today, I want to talk with you about three of the Miracle Materials sectors that I'm targeting … and to tell you about one of the best super-low-priced stocks to buy – with 300% profit potential.
So let's get down to it…
Miracle Material No. 1: Synthetic DNA
I was having dinner with the chief executive officer of a biotech firm not long ago when the conversation wound around to Miracle Materials. To underscore their importance, Miracle Materials scientists are now participants very early in the product-discovery phase of the global-tech ecosystem. Advanced technologies, you see, now require breakthroughs in a wide range of materials – from polymers to metals to medical molecules.
Nowhere is this need more obvious than with the development of synthetic vaccines.
Since synthetic vaccines stem from fragments of man-made DNA, the idea is to "program" them to fight the flu or other diseases.
I see this approach as a "Disruptive Technology" that will turn the $30 billion vaccine market inside out. Besides the flu, firms in this space are working on synthetic vaccines for leukemia, HIV, malaria, hepatitis, and cancer.
Currently, no firm has a synthetic product on the market for human use. But trust me, those products are coming. Several are in clinical trials right now – just awaiting U.S. Food and Drug Administration (FDA) approval.
This field of materials science is extremely important for a couple of reasons.
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.